Predicting Response: Rituximab

Biomarkers Predict Rituximab Response in RA

‘A further step towards the goal of personalized medicine’ in rheumatoid arthritis
medpagetoday.com

Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis

Recent works have suggested a possible link between interleukin (IL)-33 and B-cell biology. We aimed to study the possible association between serum…
Although B cell depletion with rituximab (RTX) is an effective treatment strategy in rheumatoid arthritis (RA), one third of patients do not achieve remission or low disease activity (LDA). Thus, identifying patients who will benefit from RTX is highly desirable. In the present study we investigated…
arthritis-research.biomedcentral.com

B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patients

B cells are key players in the pathogenesis of rheumatoid arthritis (RA). Although successful in 50–60% of patients with RA, anti-B-cell therapy given as rituximab could be more efficient by identifying potential responders prior to treatment. Positron emission tomography (PET) using radiolabeled ri…
arthritis-research.biomedcentral.com